Compare Torrent Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs SUVEN LIFESCIENCES - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA SUVEN LIFESCIENCES TORRENT PHARMA/
SUVEN LIFESCIENCES
 
P/E (TTM) x 58.8 20.0 293.8% View Chart
P/BV x 6.2 4.1 153.4% View Chart
Dividend Yield % 0.8 0.5 158.5%  

Financials

 TORRENT PHARMA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
SUVEN LIFESCIENCES
Mar-19
TORRENT PHARMA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs1,550338 459.0%   
Low Rs1,144169 675.0%   
Sales per share (Unadj.) Rs354.752.1 680.4%  
Earnings per share (Unadj.) Rs40.16.8 586.7%  
Cash flow per share (Unadj.) Rs64.28.6 749.4%  
Dividends per share (Unadj.) Rs14.001.50 933.3%  
Dividend yield (eoy) %1.00.6 175.7%  
Book value per share (Unadj.) Rs273.165.3 418.4%  
Shares outstanding (eoy) m169.22127.28 133.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.84.9 78.1%   
Avg P/E ratio x33.637.1 90.5%  
P/CF ratio (eoy) x21.029.6 70.9%  
Price / Book Value ratio x4.93.9 127.0%  
Dividend payout %34.922.0 159.1%   
Avg Mkt Cap Rs m227,89732,272 706.2%   
No. of employees `00014.71.1 1,358.6%   
Total wages/salary Rs m11,353661 1,717.0%   
Avg. sales/employee Rs Th4,083.06,132.2 66.6%   
Avg. wages/employee Rs Th772.3611.1 126.4%   
Avg. net profit/employee Rs Th461.3803.5 57.4%   
INCOME DATA
Net Sales Rs m60,0216,635 904.6%  
Other income Rs m2,988242 1,233.4%   
Total revenues Rs m63,0096,877 916.2%   
Gross profit Rs m13,4931,604 841.1%  
Depreciation Rs m4,086221 1,845.5%   
Interest Rs m3,08538 8,182.5%   
Profit before tax Rs m9,3101,587 586.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529718 352.2%   
Profit after tax Rs m6,781869 780.0%  
Gross profit margin %22.524.2 93.0%  
Effective tax rate %27.245.2 60.0%   
Net profit margin %11.313.1 86.2%  
BALANCE SHEET DATA
Current assets Rs m52,6236,232 844.4%   
Current liabilities Rs m52,0221,490 3,491.2%   
Net working cap to sales %1.071.5 1.4%  
Current ratio x1.04.2 24.2%  
Inventory Days Days12086 138.4%  
Debtors Days Days7683 92.3%  
Net fixed assets Rs m85,0164,043 2,102.6%   
Share capital Rs m846127 664.7%   
"Free" reserves Rs m45,3768,183 554.5%   
Net worth Rs m46,2228,310 556.2%   
Long term debt Rs m41,11518 230,980.9%   
Total assets Rs m142,43210,389 1,371.0%  
Interest coverage x4.043.1 9.3%   
Debt to equity ratio x0.90 41,526.4%  
Sales to assets ratio x0.40.6 66.0%   
Return on assets %6.98.7 79.3%  
Return on equity %14.710.5 140.2%  
Return on capital %14.219.5 72.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,5805,622 259.4%   
Fx outflow Rs m3,6001,799 200.1%   
Net fx Rs m10,9803,822 287.3%   
CASH FLOW
From Operations Rs m8,942356 2,515.3%  
From Investments Rs m-47,070-279 16,895.0%  
From Financial Activity Rs m34,174-225 -15,181.7%  
Net Cashflow Rs m-3,655-148 2,466.3%  

Share Holding

Indian Promoters % 71.5 63.4 112.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.0 -  
FIIs % 12.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 36.5 24.1%  
Shareholders   26,511 37,287 71.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   WOCKHARDT  TTK HEALTHCARE  PROCTER & GAMBLE HEALTH  BIOCON   J.B.CHEMICALS  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 17, 2019 01:43 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - PLETHICO PHARMA COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS